EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia

Agnieszka Woźniak-Szczepocka iD, Agnieszka Pawlos iD, Paulina Gorzelak-Pabiś, Marlena Broncel, Bożena Bukowska iD, Ewelina Woźniak

Journal of Cellular and Molecular Medicine · 2026-05 · 30 (10)

DOI: 10.1111/jcmm.71206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 24.05.2026. Verfasst von Agnieszka Woźniak-Szczepocka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Tissue Immunopharmacology, Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz, Lodz, Poland. Hauptthemen laut MEDLINE: Oxidative Stress, Hyperlipoproteinemia Type II, Biomarkers, PCSK9 Inhibitors. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as alirocumab and evolocumab, effectively reduce LDL‐C levels, improve cardiovascular outcomes, and are well tolerated in the treatment of heterozygous familial hypercholesterolemia (HeFH). Oxidative stress, increased in HeFH, leads to DNA damage, LDL oxidation (ox‐LDL), and reduced total plasma antioxidant capacity, which promotes the development of atherosclerosis. The aim of the study was to assess whether treatment with PCSK9 inhibitors reduces ox‐LDL, anti‐ox‐LDL antibodies, oxidative stress, and DNA damage, including 8‐OH‐Gua levels. The study included 40 patients with HeFH diagnosed clinically or genetically, and 33 healthy volunteers at low cardiovascular risk as controls. Blood samples were collected from all participants for lipid profile, Lp(a), oxidative stress markers (ox‐LDL, 8‐OHdG, anti‐oxLDL antibodies), total antioxidant capacity of plasma (TAC), and DNA damage status (using the comet assay with repair enzymes). The study showed that treatment with PCSK9 inhibitors (alirocumab or evolocumab) in HeFH patients significantly improved lipid profiles and reduced levels of oxidative stress markers such as 8‐OHdG and ox‐LDL, while increasing levels of anti‐ox‐LDL and TAC. This therapy also significantly reduced purine and pyrimidine DNA damage, although not to the level observed in the control group. The efficacy of reducing DNA damage was greater with alirocumab, which could be related to higher baseline levels of Lp(a) and oxidative damage in these patients. Treatment with PCSK9 inhibitors in HeFH patients reduces oxidative stress and DNA damage, indicating additional non‐lipid benefits that support their use in preventing atherosclerotic complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oxidative StressHyperlipoproteinemia Type IIBiomarkersPCSK9 InhibitorsHumansMaleFemaleAntibodies, Monoclonal, HumanizedDNA DamageLipoproteins, LDLAdultHeterozygoteProprotein Convertase 9Middle Aged8-Hydroxy-2'-Deoxyguanosine

Stichwörter der Autor:innen

PCSK9 inhibitorsheterozygous familial hypercholesterolaemiaoxidative DNA damageoxidative stress

Substanzen

BiomarkersPCSK9 InhibitorsAntibodies, Monoclonal, HumanizedalirocumabLipoproteins, LDLevolocumabPCSK9 protein, humanoxidized low density lipoproteinProprotein Convertase 98-Hydroxy-2'-Deoxyguanosine

Autor:innen und Institutionen

  • Laboratory of Tissue Immunopharmacology, Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz, Lodz, Poland.
  • Department of Biophysics of Environmental Pollution, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.

ORCID-Profile: Agnieszka Woźniak-Szczepocka, Agnieszka Pawlos, Bożena Bukowska

Förderung

  • Narodowe Centrum Nauki

Zitieren

APA

Woźniak-Szczepocka, A., Pawlos, A., Gorzelak-Pabiś, P., Broncel, M., Bukowska, B., & Woźniak, E. (2026). PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia. Journal of Cellular and Molecular Medicine, 30(10). https://doi.org/10.1111/jcmm.71206

Vancouver

Woźniak-Szczepocka A, Pawlos A, Gorzelak-Pabiś P, Broncel M, Bukowska B, Woźniak E. PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia. Journal of Cellular and Molecular Medicine. 2026;30(10). doi:10.1111/jcmm.71206

BibTeX
@article{WoniakSzczepocka2026,
  author = {Woźniak-Szczepocka, Agnieszka and Pawlos, Agnieszka and Gorzelak-Pabiś, Paulina and Broncel, Marlena and Bukowska, Bożena and Woźniak, Ewelina},
  title = {PCSK9 Inhibitors Reduce Oxidative Stress Biomarkers in Heterozygous Familial Hypercholesterolemia},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {10},
  doi = {10.1111/jcmm.71206}
}
Kostenlos starten →